Skip to main content
SpringerLink
Log in
Book cover

The Interventional Cardiology Training Manual pp 483–502Cite as

Percutaneous Coronary Intervention: Management of Complications

  • Chapter
  • First Online:

  • 1401 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kereiakes D, Kuntz R, Mauri L, MD M, Krucoff M. Surrogates, substudies, and real clinical end points in trials of drug-eluting stents. J Am Coll Cardiol. 2005;45(8):1206.

    Article  Google Scholar 

  2. Force m A/T, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–619.

    Article  Google Scholar 

  3. Ludman PF, British Cardiovascular Intervention Society. British cardiovascular intervention society registry for audit and quality assessment of percutaneous coronary interventions in the United Kingdom. Heart. 2011;97(16):1293–7.

    Article  Google Scholar 

  4. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J. 2003;145(1):42–6.

    Article  Google Scholar 

  5. Huber MS, Mooney JF, Madison J, Mooney MR. Use of a morphologic classification to predict clinical outcome after dissection from coronary angioplasty. Am J Cardiol. 1991;68(5):467–71.

    Article  CAS  Google Scholar 

  6. Vrints CJ. Spontaneous coronary artery dissection. Heart. 2010;96(10):801–8.

    Article  Google Scholar 

  7. Hong YJ, Jeong MH, Choi YH, Ko JS, Lee MG, Kang WY, et al. Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: a virtual histology-intravascular ultrasound analysis. Eur Heart J. 2011;32(16):2059–66.

    Article  Google Scholar 

  8. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105(5):656–62.

    Article  Google Scholar 

  9. Lee CH, Wong HB, Tan HC, Zhang JJ, Teo SG, Ong HY, et al. Impact of reversibility of no reflow phenomenon on 30-day mortality following percutaneous revascularization for acute myocardial infarction-insights from a 1,328 patient registry. J Interv Cardiol. 2005;18(4):261–6.

    Article  Google Scholar 

  10. Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol. 2010;23(5):429–36.

    Article  Google Scholar 

  11. Airoldi F, Briguori C, Cianflone D, Cosgrave J, Stankovic G, Godino C, et al. Frequency of slow coronary flow following successful stent implantation and effect of Nitroprusside. Am J Cardiol. 2007;99(7):916–20.

    Article  CAS  Google Scholar 

  12. Kaul S, Ito H. Microvasculature in acute myocardial ischemia: part I: evolving concepts in pathophysiology, diagnosis, and treatment. Circulation. 2004;109(2):146–9.

    Article  Google Scholar 

  13. Kaul S, Ito H. Microvasculature in acute myocardial ischemia: part II: evolving concepts in pathophysiology, diagnosis, and treatment. Circulation. 2004;109(3):310–5.

    Article  Google Scholar 

  14. Kaplan BM, Benzuly KH, Kinn JW, Bowers TR, Tilli FV, Grines CL, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Catheter Cardiovasc Diagn. 1996;39(2):113–8.

    Article  CAS  Google Scholar 

  15. Parikh KH, Chag MC, Shah KJ, Shah UG, Baxi HA, Chandarana AH, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol. 2007;85(3–4):476–82.

    Article  CAS  Google Scholar 

  16. Klein LW, Kern MJ, Berger P, Sanborn T, Block P, Babb J, et al. Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv. 2003;60(2):194–201.

    Article  Google Scholar 

  17. Romaguera R, Waksman R. Covered stents for coronary perforations: is there enough evidence? Catheter Cardiovasc Interv. 2011;78(2):246–53.

    Article  Google Scholar 

  18. Ellis SG, Ajluni S, Arnold AZ, Popma JJ, Bittl JA, Eigler NL, et al. Increased coronary perforation in the new device era. Incidence, classification, management, and outcome. Circulation. 1994;90(6):2725–30.

    Article  CAS  Google Scholar 

  19. Al-Lamee R, Ielasi A, Latib A, Godino C, Ferraro M, Mussardo M, et al. Incidence, predictors, management, immediate and long-term outcomes following grade III coronary perforation. JACC Cardiovasc Interv. 2011;4(1):87–95.

    Article  Google Scholar 

  20. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93(12):1515–9.

    Article  Google Scholar 

  21. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005;68(1):14–22.

    Article  CAS  Google Scholar 

  22. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–9.

    PubMed  Google Scholar 

  23. Kelly SC, Li S, Stys TP, Thompson PA, Stys AT. Reduction in contrast nephropathy from coronary angiography and percutaneous coronary intervention with ultra-low contrast delivery using an automated contrast injector system. J Invasive Cardiol. 2016;28(11):446–50.

    PubMed  Google Scholar 

  24. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48(4):692–9.

    Article  CAS  Google Scholar 

  25. Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2009;2(7):645–54.

    Article  Google Scholar 

  26. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in high-risk patients for contrast-induced acute kidney injury. Circulation. 2011;124(11):1260–9.

    Article  CAS  Google Scholar 

  27. Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (induced diuresis with matched hydration compared to standard hydration for contrast induced nephropathy prevention) trial. JACC Cardiovasc Interv. 2012;5(1):90–7.

    Article  Google Scholar 

  28. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291(19):2328–34.

    Article  CAS  Google Scholar 

  29. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124(11):1250–9.

    Article  Google Scholar 

  30. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of Rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J Am Coll Cardiol. 2014;63(1):71–9.

    Article  CAS  Google Scholar 

  31. Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med. 2006;119(2):155–62.

    Article  Google Scholar 

  32. Namasivayam S, Kalra MK, Torres WE, Small WC. Adverse reactions to intravenous iodinated contrast media: a primer for radiologists. Emerg Radiol. 2006;12(5):210–5.

    Article  Google Scholar 

  33. Leder R. How well does a history of seafood allergy predict the likelihood of an adverse reaction to i.v. contrast material? AJR Am J Roentgenol. 1997;169(3):906–7.

    Article  CAS  Google Scholar 

  34. Thomsen HS. European Society of Urogenital Radiology (ESUR) guidelines on the safe use of iodinated contrast media. Eur J Radiol. 2006;60(3):307–13.

    Article  Google Scholar 

  35. Standards for intravascular contrast administration to adult patients. 3rd ed. Royal College of Radiology; 2015.

    Google Scholar 

  36. Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol. 1991;87(4):867–72.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Conquest Hospital Hastings and Eastbourne DGH, East Sussex Healthcare NHS Trust, East Sussex, UK

    Robert T. Gerber

  2. NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK

    Robert T. Gerber, Athanasios Kosovitsas & Carlo Di Mario

  3. Careggi University Hospital, Florence, Italy

    Carlo Di Mario

Authors
  1. Robert T. Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Athanasios Kosovitsas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlo Di Mario
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Di Mario .

Editor information

Editors and Affiliations

  1. Brighton and Sussex Medical School and the Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

    Aung Myat

  2. Royal Papworth Hospital NHS Foundation Trust, Papworth Everard, Cambridge, UK

    Sarah Clarke

  3. Wessex Cardiothoracic Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK

    Nick Curzen

  4. Department of Cardiology, Bern University Hospital, Bern, Switzerland

    Stephan Windecker

  5. Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church, VA, USA

    Paul A. Gurbel

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gerber, R.T., Kosovitsas, A., Di Mario, C. (2018). Percutaneous Coronary Intervention: Management of Complications. In: Myat, A., Clarke, S., Curzen, N., Windecker, S., Gurbel, P.A. (eds) The Interventional Cardiology Training Manual. Springer, Cham. https://doi.org/10.1007/978-3-319-71635-0_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-71635-0_32

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-71633-6

  • Online ISBN: 978-3-319-71635-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation